Cytomegalovirus (CMV) Infection Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Key Companies - Moderna, Nobelpharma, Hookipa Biotech, Biotest, AlloVir, Merck, VBI Vaccines, SpyBiotech

As per DelveInsight, the Cytomegalovirus (CMV) Infection Market is anticipated to evolve immensely in the coming years owing to the increase in the patient population and the expected entry of emerging therapies in the market.

DelveInsight's "Cytomegalovirus (CMV) Infection Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cytomegalovirus (CMV) Infection Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Cytomegalovirus (CMV) Infection therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Cytomegalovirus (CMV) Infection treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Cytomegalovirus (CMV) Infection: An Overview
Cytomegalovirus (CMV) Infections is a type of herpesvirus (herpesvirus type 5) with a wide range of symptoms: from no symptoms to fever and fatigue (resembling infectious mononucleosis) to severe symptoms involving the eyes, brain, or other internal organs. It is a common virus for people of all ages; however, a healthy person's immune system usually keeps the virus from causing illness. Blood tests show that 60-90% of adults have had a CMV Infections infection at some time.

CMV Infections may cause symptoms soon after infection, and can also remain dormant (inactive) in various tissues for life. Various stimuli can reactivate the dormant CMV Infections, resulting in virus growth, which can sometimes cause disease. The lungs, gastrointestinal tract, brain, spinal cord, or eyes may be infected.

When the infection threatens life or eyesight, an antiviral drug (valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination) may be given. These drugs may be given by mouth or by vein. When CMV Infections retinitis is very severe, the drugs may also be injected directly into the eye. These drugs have serious side effects, which increase the demand and need for more potential therapies.

Cytomegalovirus (CMV) Infection Market Key Facts
• In 2022, the total diagnosed cases of CMV were found out to be 111,100+ in the 7MM. These cases are expected to increase by 2032. It was also found that 40% of solid organ transplant patients are diagnosed with CMV in the US.
• Among the European countries, France had the highest diagnosed cases of CMV with 8,800+ cases, followed by the UK which had a diagnosed population of 7,400+ in 2022. On the other hand, Italy had the lowest diagnosed incident population of 3,800+ in 2022.
• In 2022, a total of 3,100+ incident population of HSCT was estimated in Germany. These cases are further expected to increase. DelveInsight also estimates that the number of CMV patients from HSCT patients are found out to be 1,100+ in 2022 in Germany.
• Japan had 7,200+ diagnosed cases of CMV in 2022, which is expected to increase during the forecast period.
• According to DelveInsight, CMV Infections affect males and females equally.

Get a Detailed Overview of the Evolving Cytomegalovirus (CMV) Infection Market Trends @
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Cytomegalovirus (CMV) Infection Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Cytomegalovirus (CMV) Infection therapies in the market. It also provides a detailed assessment of the Cytomegalovirus (CMV) Infection market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Cytomegalovirus (CMV) Infection drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Cytomegalovirus (CMV) Infection Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Cytomegalovirus (CMV) Infection Epidemiology
The epidemiology section covers detailed insights into the historical, and current Cytomegalovirus (CMV) Infection patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Cytomegalovirus (CMV) Infection Epidemiology Segmented as -
• Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the 7MM [2019-2032]
• Number of Infants born with Congenital CMV in the 7MM [2019-2032]
• Number of CMV Patients among SOT in the 7MM [2019-2032]
• CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the 7MM [2019-2032]
• CMV Retinitis among HIV Patients in the 7MM [2019-2032]
• Number of Refractory CMV Patients after HSCT/SOT in the 7MM [2019-2032]

Get Key Insights Into the Evolving Cytomegalovirus (CMV) Infection Epidemiology Trends @
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Cytomegalovirus (CMV) Infection Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cytomegalovirus (CMV) Infection market or expected to be launched during the study period. The analysis covers the market share by Cytomegalovirus (CMV) Infection drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Cytomegalovirus (CMV) Infection Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Cytomegalovirus (CMV) Infection Market @
https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Cytomegalovirus (CMV) Infection Therapeutics Assessment
CMV infection or reactivation can lead to serious complications in hosts whose immune systems are either compromised by disease or suppressed, which is common following stem cell and solid organ transplants. The treatment market for CMV infections is divided into Prophylactic and Therapeutic Drugs.

Prophylactic Management: Transmission of cytomegalovirus is often preventable because it is most often transmitted through infected bodily fluids that come in contact with hands and then are absorbed through the nose or mouth of a susceptible person. There are two major strategies for CMV disease prevention after liver transplantation that include preemptive therapy and antiviral prophylaxis.

For preemptive therapy, patients are monitored for evidence of CMV replication by sensitive assays, most commonly using quantitative nucleic acid amplification tests by PCR and less commonly by detection of pp65 antigenemia, and upon the detection of asymptomatic CMV replication, antiviral therapy is administered preemptively to prevent progression to symptomatic clinical disease.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Cytomegalovirus (CMV) Infection. Currently, Moderna is leading the therapeutics market with its Cytomegalovirus (CMV) Infection drug candidates in the most advanced stage of clinical development.

Recent Developments in the Cytomegalovirus (CMV) Infection Market
1. On June 06, 2023, Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for PREVYMIS® (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]) following a priority review.
2. On November 11, 2022, Takeda (TSE:4502/NYSE: TAK) announced that the European Commission (EC) has granted Marketing Authorization for LIVTENCITYTM (maribavir) for the treatment of cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet, in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

Leading Companies in the Cytomegalovirus (CMV) Infection Therapeutics Market Include
Some of the prominent players in the Cytomegalovirus (CMV) Infection Therapeutics Market include Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others.

Emerging and Marketed Cytomegalovirus (CMV) Infection Therapies Covered in the Report Include
Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Cytomegalovirus (CMV) Infection. Some of the emerging therapies in the pipeline include mRNA-1647 (Moderna), Posoleucel (AlloVir), SYN002 (Synklino), and others.

Learn More About the Emerging Therapies and key Companies in the Cytomegalovirus (CMV) Infection Therapeutics Market @
https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cytomegalovirus (CMV) Infection Competitive Intelligence Analysis
4. Cytomegalovirus (CMV) Infection Market Overview at a Glance
5. Cytomegalovirus (CMV) Infection Background and Overview
6. Cytomegalovirus (CMV) Infection Patient Journey
7. Cytomegalovirus (CMV) Infection Epidemiology and Patient Population
8. Cytomegalovirus (CMV) Infection Treatment Algorithm, Current Treatment, and Medical Practices
9. Cytomegalovirus (CMV) Infection Unmet Needs
10. Key Endpoints of Cytomegalovirus (CMV) Infection Treatment
11. Cytomegalovirus (CMV) Infection Marketed Products
12. Cytomegalovirus (CMV) Infection Emerging Therapies
13. Cytomegalovirus (CMV) Infection Seven Major Market Analysis
14. Attribute Analysis
15. Cytomegalovirus (CMV) Infection Market Outlook (7 major markets)
16. Cytomegalovirus (CMV) Infection Access and Reimbursement Overview
17. KOL Views on the Cytomegalovirus (CMV) Infection Market.
18. Cytomegalovirus (CMV) Infection Market Drivers
19. Cytomegalovirus (CMV) Infection Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.